Aktuellt
SENASTE
Redeye updates our outlook after the SEK 440m (gross) directed rights issue priced at SEK 275, will allow XVIVO to push the Liver Assist and the Heart solution onto the US market and rapidly ramp up the production capacity for recurring margin sales. In our view, this is positive, considering the long sales runway, short pay-back times and XVIVO's better use of its existing toolbox. Our base case is SEK 450 (Bull 950, Bear 105).
LÄS MER
